Suppr超能文献

肝硬化胃静脉曲张出血的二级预防:在内镜联合治疗基础上加用非选择性β受体阻滞剂

Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non-Selective Beta-Blockers to Endoscopic Combined Treatment.

作者信息

Wu Ling, Huang Xiaoquan, Li Feng, Jiang Siyu, Ni Liyuan, Ai Yingjie, Schuppan Detlef, Chen Shiyao

机构信息

Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.

Institute of Translational Immunology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

出版信息

United European Gastroenterol J. 2025 May;13(4):586-598. doi: 10.1002/ueg2.12739. Epub 2024 Dec 30.

Abstract

BACKGROUND

It remains unclear whether the addition of non-selective beta-blockers (NSBB) provides further benefit after combined use of tissue adhesive and endoscopic variceal ligation for bleeding gastroesophageal varices.

OBJECTIVE

This is the first cohort study comparing the secondary prophylactic efficacy of adding NSBB to combined endoscopic treatment in cirrhotic patients with gastric varices (without inclusion of isolated gastric varices [IGVs], which are rare in patients with cirrhosis without splanchnic thrombosis).

METHODS

We retrospectively analyzed two matched large cohorts of cirrhotic patients with gastric varices who received combined endoscopic treatment and were assigned to receive NSBB treatment or not as secondary prophylaxis. Further sub-analyses were performed. The 5-year overall survival and rebleeding rates were compared.

RESULTS

A total of 490 patients were enrolled, 130 of whom took NSBB. After propensity score matching (PSM), both groups comprised 130 patients. No significant difference between the NSBB and non-NSBB groups was observed regarding 5-year survival (87.40% vs. 83.64%, HR 0.62, 95% CI 0.33-1.17), while NSBB decreased the 5-year rebleeding rate from 45.7% to 30.64% (HR 0.57, 95% CI 0.39-0.82). The same was true when comparing the 2 groups after PSM. NSBB (HR 0.54, 95% CI 0.37-0.79) and splenectomy (HR 0.65, 95% CI 0.44-0.96) independently reduced rebleeding but did not affect survival. In patients without splenectomy, NSBB treatment improved survival (HR 0.43, 95% CI 0.21-0.89) and reduced rebleeding (HR 0.52, 95% CI 0.34-0.78).

CONCLUSION

We show for the first time that adding NSBB to combined endoscopic therapy significantly reduced recurrent variceal bleeding in cirrhotic patients but did not improve overall survival, except for patients without splenectomy. The addition of NSBB for patients receiving combined endoscopic treatment of gastroesophageal varices provides benefits but does not prolong overall survival.

摘要

背景

在组织粘合剂与内镜下静脉曲张结扎术联合用于治疗食管胃静脉曲张出血后,加用非选择性β受体阻滞剂(NSBB)是否能带来更多益处仍不明确。

目的

这是第一项队列研究,比较在肝硬化合并胃静脉曲张患者(不包括孤立性胃静脉曲张[IGV],在无内脏血栓形成的肝硬化患者中罕见)中,加用NSBB至联合内镜治疗后的二级预防效果。

方法

我们回顾性分析了两个匹配的大型肝硬化合并胃静脉曲张患者队列,这些患者接受了联合内镜治疗,并被分配接受或不接受NSBB治疗作为二级预防。进行了进一步的亚组分析。比较了5年总生存率和再出血率。

结果

共纳入490例患者,其中130例服用NSBB。倾向评分匹配(PSM)后,两组各有130例患者。NSBB组和非NSBB组在5年生存率方面无显著差异(87.40%对83.64%,HR 0.62,95%CI 0.33 - 1.17),而NSBB将5年再出血率从45.7%降至30.64%(HR 0.57,95%CI 0.39 - 0.82)。PSM后比较两组时情况相同。NSBB(HR 0.54,95%CI 0.37 - 0.79)和脾切除术(HR 0.65,95%CI 0.44 - 0.96)可独立降低再出血,但不影响生存率。在未行脾切除术的患者中,NSBB治疗可提高生存率(HR 0.43,95%CI 0.21 - 0.89)并降低再出血率(HR 0.52,95%CI 0.34 - 0.78)。

结论

我们首次表明,在内镜联合治疗中加用NSBB可显著降低肝硬化患者静脉曲张再出血,但除未行脾切除术的患者外,并未改善总生存率。对于接受食管胃静脉曲张联合内镜治疗的患者,加用NSBB有获益,但不会延长总生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e524/12090826/26d14fb5a70f/UEG2-13-586-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验